HC Wainwright & Co. Reiterates Buy on Absci, Maintains $16 Price Target

10/12/2026
Impact: 80
Healthcare

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Absci (NASDAQ: ABSI) and maintained a price target of $16 for the company's stock.

AI summary, not financial advice

Share: